Long term outcome of catastrophic antiphospholipid syndrome survivors. 2003

D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, NY, USA. derkan@pol.net

BACKGROUND Catastrophic antiphospholipid syndrome (APS) is defined as life threatening multiple organ thromboses developing simultaneously or over a short period. The survival rate of catastrophic APS is about 50%, but the long term outcome of patients who survive is unknown. OBJECTIVE To determine the long term outcome of patients with catastrophic APS and provide further information on patients who survived. METHODS The clinical characteristics and outcomes of 130 patients with catastrophic APS have been reported previously. Six new cases were recently added to this series. Based on these publications, the authors who reported patients who had survived were contacted. Each author was asked (a) what treatment they gave their patients after the catastrophic APS; (b) if their patients had any further thrombosis. RESULTS 63/136 (46%) patients died at the initial event. Of the remaining 73 patients, information was available for 58 (79%). Thirty eight (66%) patients did not develop further APS related events during an average follow up of 67.2 months. Eleven (19%) patients developed further APS related events but were still alive. No patients developed further catastrophic APS. Nine (16%) patients died: due to multiple organ failure (three patients); myelofibrosis (one); pneumonia (one); and APS related events (four). CONCLUSIONS Sixty six per cent of patients who survive an initial catastrophic APS event remained symptom free with anticoagulation during an average follow up of 67.2 months. Twenty six per cent of the survivors developed further APS related events and the mortality rate of these patients was about 25%.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect

Related Publications

D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
June 2009, Polskie Archiwum Medycyny Wewnetrznej,
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
February 2006, Nature clinical practice. Rheumatology,
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
June 2012, La Revue de medecine interne,
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
August 2013, Clinical & experimental ophthalmology,
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
October 2003, Current rheumatology reports,
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
April 2003, Mayo Clinic proceedings,
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
January 2015, Wiadomosci lekarskie (Warsaw, Poland : 1960),
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
January 2016, Case reports in rheumatology,
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
February 1997, Presse medicale (Paris, France : 1983),
D Erkan, and R A Asherson, and G Espinosa, and R Cervera, and J Font, and J-C Piette, and M D Lockshin, and
January 2006, Pathophysiology of haemostasis and thrombosis,
Copied contents to your clipboard!